Introduction {#Sec1}
============

Patients with anti-acetylcholine receptor antibody-positive (AChR+), refractory, generalized myasthenia gravis (gMG) experience muscle weakness, which is associated with complement-mediated damage at the neuromuscular junction \[[@CR1], [@CR2]\]. Patients with MG experience muscle fatigability (difficulty initiating or sustaining muscle activities) \[[@CR1], [@CR3]\]. Perceived fatigue (a feeling of tiredness, lack of energy, and difficulty concentrating; referred to as fatigue hereafter) is also an important clinical issue for these patients and may be distinct from muscle weakness and fatigability \[[@CR3]--[@CR7]\].

Validated MG-specific assessments used to measure disease severity and response to intervention include the patient-reported MG Activities of Daily Living (MG-ADL) and 15-item MG Quality of Life (MG-QOL15) scales, and the physician-completed Quantitative MG (QMG) assessment of muscle strength \[[@CR8]--[@CR10]\]. None of these evaluate the impact of fatigue in gMG. The Quality of Life in Neurological Disorders (Neuro-QOL) assessment is designed to measure health-related quality of life across 13 subscales in patients with neurological conditions \[[@CR11]\]. Neuro-QOL has been validated in a range of disorders, including multiple sclerosis, Parkinson's disease, and epilepsy, but not in MG \[[@CR12]--[@CR14]\]. The Neuro-QOL Fatigue subscale comprises a 19-item, patient self-assessment of fatigue that encompasses 'sensations ranging from tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that decrease one's capacity for physical, functional, social, and mental activities' \[[@CR15]\]. A short form Neuro-QOL Fatigue subscale is also available; this was recently validated in patients with MG \[[@CR7]\].

Eculizumab is a humanized monoclonal antibody that binds to complement protein C5, inhibiting the activation of the terminal complement component proteins that are believed to mediate damage at the neuromuscular junction in AChR+ gMG \[[@CR2], [@CR16]\]. In the phase 3 REGAIN study, eculizumab demonstrated clinically meaningful improvements in patients with AChR+ refractory gMG, evaluated using MG-ADL, QMG, and MG-QOL15 assessments (NCT01997229) \[[@CR17]\].

The current analysis investigated the effect of eculizumab versus placebo on fatigue in patients with AChR+ refractory gMG, and assessed the relationship between fatigue and MG-specific measures. We used the Neuro-QOL Fatigue subscale to evaluate changes in patients' self-reported assessment of fatigue during REGAIN and its open-label extension study (NCT02301624; interim analysis, 31 December 2017) \[[@CR18]\]. We also measured the correlation between outcomes measured using the Neuro-QOL Fatigue subscale and the MG-ADL, QMG, and MG-QOL15 scales in REGAIN.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

REGAIN was a 26-week, phase 3, randomized, double-blind, placebo-controlled study evaluating eculizumab efficacy and safety \[[@CR17]\]. Briefly, patients were randomized 1:1 to receive eculizumab (*n* = 62; induction: 900 mg for 4 weeks; maintenance: 1200 mg at week 4 and then every 2 weeks until week 26) or placebo (*n* = 63) \[[@CR17]\]. The primary endpoint was the change in MG-ADL total score with eculizumab versus placebo.

The Neuro-QOL Fatigue subscale was used to assess fatigue, and the MG-ADL, QMG, and MG-QOL15 scales were used to measure MG-specific activities of daily living, muscle strength, and quality of life, respectively. In REGAIN, all assessments were performed at baseline (day 1), every 4 weeks to week 20, and at week 26. MG-ADL and QMG assessments were also conducted at weeks 1, 2, and 3. Details of scoring for MG-ADL, QMG, and MG-QOL15 during REGAIN have been reported previously; briefly, for each measure, a reduction from baseline total score indicates improvement \[[@CR17]\]. The response scale for Neuro-QOL Fatigue items was: 1 = never; 2 = rarely; 3 = sometimes; 4 = often; and 5 = always. The range of potential total scores was 19--95. Higher Neuro-QOL Fatigue subscale total scores indicate greater fatigue; a reduction from baseline total score indicates improvement \[[@CR15]\].

Patients who completed REGAIN could enroll into the extension study \[[@CR18]\]. Following a 4-week blinded induction phase, all patients received open-label eculizumab (1200 mg) at week 4 and every 2 weeks thereafter. Assessments occurred as in REGAIN to week 26, then at week 40, week 52, and every 6 months \[[@CR18]\].

Statistical analysis {#Sec4}
--------------------

A repeated-measures model was used to test whether changes in Neuro-QOL Fatigue total scores from baseline to REGAIN week 26 for eculizumab and placebo were equal (Fig. [1](#Fig1){ref-type="fig"}). Model-estimated changes from REGAIN baseline data were reported up to open-label study week 52 (interim analysis, 31 December 2017) (Fig. [1](#Fig1){ref-type="fig"}). To evaluate the treatment effect on Neuro-QOL Fatigue subscale individual items at REGAIN week 26, a repeated-measures proportional odds model was implemented using the GEEORD SAS Macro (Table [2](#Tab2){ref-type="table"}) \[[@CR19]\]. Missing scores were not imputed in either model.

Fig. 1Change in Neuro-QOL Fatigue subscale total score from REGAIN baseline to week 52 of the open-label study using a repeated-measures model.^aa^A repeated-measures model using the restricted maximum likelihood for the changes from baseline was used to compare the two treatment groups at each assessment visit and over time. The model included the following terms: treatment, visit, treatment by visit interaction, pooled Myasthenia Gravis Foundation of America (MGFA) randomization stratification variable (based on their MGFA classification at screening, patients were assigned to one of two categories: IIa/IIIa/IVa \[a, symptoms predominantly affecting limb or axial muscles, or both\] or IIb/IIIb/IVb \[b, symptoms predominantly affecting oropharyngeal or respiratory muscles, or both\]), and Neuro-QOL Fatigue total score at baseline. ^b^Number of patients who completed the assessment at each time point. Some patients did not complete all items of the questionnaire at every timepoint. When this occurred, total scores could not be computed at that time point. Missing scores were not imputed. *BL* baseline, *CI* confidence interval, *Neuro-QOL Fatigue* Quality of Life in Neurological Disorders Fatigue subscale, *REGAIN* Eculizumab for REfractory GenerAlIzed MyastheNia Gravis

Pearson correlation coefficients (*r*) were calculated for the treatment arms using observed changes from baseline to REGAIN week 26 for Neuro-QOL Fatigue total scores versus observed changes for MG-ADL, QMG, and MG-QOL15 total scores (Fig. [2](#Fig2){ref-type="fig"}). The strength of association for absolute values of *r* was classified as follows: very weak, 0--0.19; weak, 0.2--0.39; moderate, 0.40--0.59; strong, 0.6--0.79; and very strong, 0.8--1 \[[@CR20]\]. Within each treatment arm, the null hypothesis was *r* = 0.4 (the lower limit for moderate correlations). For all evaluations, statistical significance was established using a two-sided *p* value of less than 0.05, without any multiplicity adjustment.

Fig. 2Correlation between change from REGAIN baseline to week 26, in Neuro-QOL Fatigue subscale total score and **a** MG-ADL, **b** QMG, and **c** MG-QOL15 total scores by treatment group (eculizumab, *n* = 54; placebo, *n* = 58). Improvements in Neuro-QOL Fatigue total score correlated with improvements in **a** MG-ADL, **b** QMG, and **c** MG-QOL15 total scores more strongly in patients treated with eculizumab than in those who received placebo. Within treatment arms, the null hypothesis was *r* = 0.4 (the lower limit for moderate correlations). *CI* confidence interval, *MG-ADL* Myasthenia Gravis-Activities of Daily Living, *MG-QOL15* 15-item Myasthenia Gravis Quality of Life, *Neuro-QOL Fatigue* Quality of Life in Neurological Disorders Fatigue subscale, *QMG* quantitative myasthenia gravis

Results {#Sec5}
=======

Baseline demographics and characteristics were similar between treatment groups, with the exception of a higher proportion of Asian patients in the placebo group (Table [1](#Tab1){ref-type="table"}). All patients were assessed using the Neuro-QOL Fatigue subscale (Table [1](#Tab1){ref-type="table"}); mean (standard deviation) baseline total score was 64.1 (14.1) for the eculizumab group and 61.8 (15.9) for the placebo group.

Table 1Baseline demographics and characteristics of patients in REGAINEculizumab (*n* = 62)Placebo (*n* = 63)Age at diagnosis, years, mean (SD)38.0 (17.8)38.1 (19.6)Age at first study dose, years, mean (SD)47.5 (15.7)46.9 (18.0)Sex, *n* (%) Male21 (34%)22 (35%) Female41 (66%)41 (65%)Race, *n* (%) Asian3 (5%)16 (25%) Black or African American03 (5%) White53 (85%)42 (67%) Other6 (10%)2 (3%) BMI, kg/m^2^, mean (SD)31.4 (9.0)30.5 (8.4) Myasthenia gravis duration, years, mean (SD)9.9 (8.1)9.2 (8.4) Neuro-QOL Fatigue total score, mean (SD); median^a^64.1 (14.1); 64.061.8 (15.9); 64.0Neuro-QOL Fatigue item score, mean (SD); median^a^ I felt exhausted3.6 (0.82); 4.03.5 (1.09); 4.0 I felt that I had no energy3.7 (1.04); 4.03.7 (0.98); 4.0 I felt fatigued3.8 (0.88); 4.03.7 (0.91); 4.0 I was too tired to do my household chores3.5 (1.01); 4.03.3 (1.03); 3.0 I was too tired to leave the house3.2 (1.01); 3.03.2 (0.99); 3.0 I was frustrated by being too tired to do the things I wanted to do3.7 (1.08); 4.03.4 (1.21); 3.0 I felt tired3.8 (0.80); 4.03.8 (0.97); 4.0 I had to limit my social activity because I was tired3.6 (1.00); 4.03.4 (1.13); 4.0 I needed help doing my usual activities because of my fatigue3.0 (1.24); 3.02.9 (1.22); 3.0 I needed to sleep during the day3.3 (1.29); 3.03.4 (1.23); 4.0 I had trouble starting things because I was too tired3.3 (0.89); 3.03.1 (1.13); 3.0 I had trouble finishing things because I was too tired3.5 (0.99); 4.03.2 (1.06); 3.0 I was too tired to take a short walk3.4 (1.19); 4.03.1 (1.29); 3.0 I was too tired to eat2.6 (1.07); 3.02.3 (1.09); 2.0 I was so tired that I had to rest during the day3.7 (1.06); 4.03.6 (1.07); 4.0 I felt weak all over3.3 (1.07); 3.03.3 (1.13); 3.0 I needed help doing my usual activities because of weakness2.9 (1.24); 3.02.9 (1.18); 3.0 I had to limit my social activity because I was physically weak3.3 (1.23); 3.03.3 (1.04); 3.0 I had to force myself to get up and do things because I was physically too weak3.0 (1.18); 3.02.9 (1.17); 3.0*SD* standard deviation^a^Some patients did not complete all items of the questionnaire. When this occurred, total scores could not be computed and the specific item score is missing for those patients

Eculizumab was associated with greater improvements in fatigue than placebo. At REGAIN week 26, patients receiving eculizumab had a model-estimated mean change from baseline Neuro-QOL Fatigue total score of − 16.3 (95% confidence interval \[CI\]: − 20.8, − 11.8) versus − 7.7 (95% CI − 12.1, − 3.3) for placebo (model-estimated mean difference − 8.6 \[95% CI − 14.8, − 2.3; *p* = 0.0081\]) (Fig. [1](#Fig1){ref-type="fig"}). By week 4 of the open-label study, patients who had received eculizumab in both studies (eculizumab/eculizumab arm) had reductions from REGAIN baseline of − 17.8 (95% CI − 22.5, − 13.0) compared with − 17.4 (95% CI − 22.0, − 12.9) for patients who received placebo during REGAIN and eculizumab during the open-label study (placebo/eculizumab arm) (Fig. [1](#Fig1){ref-type="fig"}). Improvements in Neuro-QOL Fatigue score, from REGAIN baseline, were maintained through open-label study week 52 (--17.5 \[95% CI − 22.5, − 12.5\] and − 15.7 \[95% CI − 20.5, − 10.9\] for the eculizumab/eculizumab and placebo/eculizumab arms, respectively).

At REGAIN week 26, the proportional odds ratios for all 19 Neuro-QOL Fatigue items were greater than 1, indicating that a greater proportion of eculizumab-treated patients than placebo-treated patients selected lower scoring responses (i.e., more selected 'never' or 'rarely,' and fewer selected 'often' or 'always') (Table [2](#Tab2){ref-type="table"}). This was statistically significant for 15 of 19 items (range of common odds ratios with *p* \< 0.05: 1.8--2.9; Table [2](#Tab2){ref-type="table"}), indicating that eculizumab treatment was associated with milder fatigue than placebo.

Table 2Neuro-QOL Fatigue individual item responses and results from a repeated-measures proportional odds model at REGAIN week 26ParameterTreatmentObserved responses for Neuro-QOL Fatigue items at REGAIN week 26Repeated-measures model estimate for REGAIN week 261 = Never, *n* (%)2 = Rarely, *n* (%)3 = Sometimes, *n* (%)4 = Often, *n* (%)5 = Always, *n* (%)Proportional odds ratio (95% CI)^b^*p* value for odds ratio^b,c^*p* value for proportional odds assumption^d^I felt exhaustedECU (*n*^*a*^ = 57)9 (15.8)14 (24.6)19 (33.3)13 (22.8)2 (3.5)2.4 (1.3, 4.4)0.00380.1099PLC (*n*^*a*^ = 60)5 (8.3)9 (15.0)25 (41.7)16 (26.7)5 (8.3)I felt that I had no energyECU (*n*^a^ = 57)9 (15.8)15 (26.3)21 (36.8)9 (15.8)3 (5.3)1.9 (1.1, 3.5)0.03220.5692PLC (*n*^a^ = 60)5 (8.3)10 (16.7)23 (38.3)15 (25.0)7 (11.7)I felt fatiguedECU (*n*^a^ = 57)7 (12.3)16 (28.1)22 (38.6)8 (14.0)4 (7.0)1.8 (1.0, 3.4)0.04670.3357PLC (*n*^a^ = 60)2 (3.3)14 (23.3)24 (40.0)15 (25.0)5 (8.3)I was too tired to do my household choresECU (*n*^a^ = 56)16 (28.6)15 (26.8)13 (23.2)7 (12.5)5 (8.9)1.9 (1.0, 3.4)0.04370.6454PLC (*n*^a^ = 60)11 (18.3)11 (18.3)19 (31.7)17 (28.3)2 (3.3)I was too tired to leave the houseECU (*n*^a^ = 57)22 (38.6)12 (21.1)12 (21.1)8 (14.0)3 (5.3)2.5 (1.4, 4.7)0.00330.2162PLC (*n*^a^ = 60)12 (20.0)11 (18.3)20 (33.3)15 (25.0)2 (3.3)I was frustrated by being too tired to do the things I wanted to doECU (*n*^a^ = 57)20 (35.1)14 (24.6)11 (19.3)8 (14.0)4 (7.0)2.5 (1.4, 4.5)0.00320.4059PLC (*n*^a^ = 60)14 (23.3)7 (11.7)16 (26.7)18 (30.0)5 (8.3)I felt tiredECU (*n*^a^ = 57)9 (15.8)9 (15.8)22 (38.6)12 (21.1)5 (8.8)2.3 (1.2, 4.4)0.00920.3737PLC (*n*^a^ = 60)0 (0.0)9 (15.0)26 (43.3)17 (28.3)8 (13.3)I had to limit my social activity because I was tiredECU (*n*^a^ = 57)15 (26.3)16 (28.1)13 (22.8)9 (15.8)4 (7.0)2.6 (1.4, 4.7)0.00260.6225PLC (*n*^a^ = 60)8 (13.3)11 (18.3)18 (30.0)17 (28.3)6 (10.0)I needed help doing my usual activities because of my fatigueECU (*n*^a^ = 57)26 (45.6)10 (17.5)10 (17.5)7 (12.3)4 (7.0)2.3 (1.2, 4.2)0.01040.5279PLC (*n*^a^ = 60)14 (23.3)11 (18.3)20 (33.3)12 (20.0)3 (5.0)I needed to sleep during the dayECU (*n*^a^ = 57)14 (24.6)14 (24.6)13 (22.8)10 (17.5)6 (10.5)1.5 (0.8, 2.7)0.21640.4892PLC (*n*^a^ = 60)12 (20.0)7 (11.7)16 (26.7)15 (25.0)10 (16.7)I had trouble starting things because I was too tiredECU (*n*^a^ = 57)16 (28.1)18 (31.6)13 (22.8)6 (10.5)4 (7.0)2.2 (1.2, 4.1)0.00960.1930PLC (*n*^a^ = 60)15 (25.0)7 (11.7)18 (30.0)13 (21.7)7 (11.7)I had trouble finishing things because I was too tiredECU (*n*^a^ = 57)20 (35.1)13 (22.8)13 (22.8)8 (14.0)3 (5.3)2.5 (1.4, 4.5)0.00270.8333PLC (*n*^a^ = 60)12 (20.0)11 (18.3)18 (30.0)13 (21.7)6 (10.0)I was too tired to take a short walkECU (*n*^a^ = 57)19 (33.3)14 (24.6)11 (19.3)9 (15.8)4 (7.0)1.5 (0.8, 2.7)0.18960.9608PLC (*n*^a^ = 60)17 (28.3)10 (16.7)15 (25.0)14 (23.3)4 (6.7)I was too tired to eatECU (*n*^a^ = 57)30 (52.6)12 (21.1)10 (17.5)1 (1.8)4 (7.0)1.2 (0.6, 2.3)0.53650.9093PLC (*n*^a^ = 60)25 (41.7)17 (28.3)11 (18.3)7 (11.7)0 (0.0)I was so tired that I had to rest during the dayECU (*n*^a^ = 57)10 (17.5)11 (19.3)13 (22.8)17 (29.8)6 (10.5)1.2 (0.7, 2.3)0.46970.4873PLC (*n*^a^ = 60)9 (15.0)8 (13.3)19 (31.7)14 (23.3)10 (16.7)I felt weak all overECU (*n*^a^ = 57)23 (40.4)9 (15.8)13 (22.8)7 (12.3)5 (8.8)2.5 (1.4, 4.7)0.00320.4309PLC (*n*^a^ = 60)12 (20.0)12 (20.0)14 (23.3)17 (28.3)5 (8.3)I needed help doing my usual activities because of weaknessECU (*n*^a^ = 57)26 (45.6)12 (21.1)10 (17.5)6 (10.5)3 (5.3)2.3 (1.2, 4.2)0.00950.3340PLC (*n*^a^ = 60)14 (23.3)13 (21.7)17 (28.3)14 (23.3)2 (3.3)I had to limit my social activity because I was physically weakECU (*n*^a^ = 57)19 (33.3)18 (31.6)6 (10.5)10 (17.5)4 (7.0)2.9 (1.6, 5.3)0.00060.1119PLC (*n*^a^ = 60)10 (16.7)8 (13.3)20 (33.3)15 (25.0)7 (11.7)I had to force myself to get up and do things because I was physically too weakECU (*n*^a^ = 57)25 (43.9)15 (26.3)9 (15.8)5 (8.8)3 (5.3)2.1 (1.1, 4.0)0.01720.0927PLC (*n*^a^ = 60)19 (31.7)7 (11.7)18 (30.0)15 (25.0)1 (1.7)The *p* values associated with the proportional odds assumption indicated that this assumption was upheld for each item*CI* confidence interval, *ECU* eculizumab, *Neuro-QOL* Quality of Life in Neurological Disorders, *PLC* placebo^a^Number of patients who completed the assessment at week 26; missing scores were not imputed for patients who did not complete the assessment (ECU, *n* = 5 \[*n* = 6 for 'I was too tired to do my household chores'\]; PLC, *n* = 3)^b^Proportional odds ratios and *p*values are based on a repeated-measures ordinal regression (implemented using the GEEORD SAS Macro). The model has the ordinal response (for each parameter) at each visit as the dependent variable with terms for treatment, visit, and treatment by visit interaction, assuming exchangeable correlation structure. A higher odds ratio indicates that eculizumab-treated patients are more likely to answer in the lower response categories than those receiving placebo at week 26 for that item^c^*p* values are not adjusted for multiple comparisons^d^A *p *value for proportional odds assumption \< 0.05 may indicate non-proportionality

For the eculizumab group, there were significant correlations (i.e., different from *r* = 0.4) for changes in total score from baseline to REGAIN week 26 between Neuro-QOL Fatigue and MG-QOL15 (*r* = 0.74), MG-ADL (*r* = 0.70), and QMG (*r* = 0.64) (Fig. [2](#Fig2){ref-type="fig"}). For the placebo-treated group, a strong correlation for change from baseline to REGAIN week 26 was observed between Neuro-QOL Fatigue and MG-QOL15 (*r* = 0.65); conversely, correlations between Neuro-QOL Fatigue and QMG and MG-ADL were not significantly different from *r* = 0.4 (*r* = 0.45 \[moderate\] and *r* = 0.35 \[weak\]) (Fig. [2](#Fig2){ref-type="fig"}).

Discussion {#Sec6}
==========

This was the first use of the extended Neuro-QOL Fatigue subscale in patients with AChR+ refractory gMG. In REGAIN, levels of fatigue at baseline were generally consistent with previously published reports for MG; however, in these previous studies, fatigue was assessed using a variety of measures, and patients were not explicitly refractory to treatment \[[@CR6], [@CR7], [@CR21]\].

At REGAIN week 26, eculizumab-treated patients were approximately twice as likely to report improved scores for the 15 of 19 subscale items where significant differences were observed, compared with placebo (range for odds ratios: 1.8--2.9; Table [2](#Tab2){ref-type="table"}).

Patients who received eculizumab for the first time during the open-label study had similar improvements in fatigue to those seen with eculizumab during REGAIN. These were sustained through to week 52 of the open-label study and were consistent with previously reported improvements in MG-validated measures of disease burden (QMG, MG-ADL, and MG-QOL15) \[[@CR17], [@CR22]\]. The consistently strong, positive correlations between changes in Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG observed in eculizumab-treated patients suggest that the effect of eculizumab on fatigue is a valid clinical outcome in this patient population. The greater variability in observed correlations in placebo-treated patients may reflect the degree of similarity between the items assessed by the Neuro-QOL Fatigue subscale and those assessed by the MG-QOL15 (most similar, strong correlation), the MG-ADL (some similarities, moderate correlation), and the QMG (least similar, weak correlation).

Our findings suggest that the Neuro-QOL Fatigue subscale may be used to assess the clinical impact of perceived fatigue and the effect of therapeutic interventions in patients with AChR+ refractory gMG. Use of this scale demonstrated that eculizumab provided sustained, clinically meaningful improvements in fatigue. Our results contribute to the consistency and totality of the data demonstrating that eculizumab lowers the clinical burden in patients with AChR+ refractory gMG.
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